Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

LQDA - Liquidia Corporation So'nggi Yangiliklar | Finranks

Home

/

LQDA

L

Liquidia Corporation (LQDA)

NCM – Real vaqt narxi. Valyuta: USD

80.95

-7.10 (-8.06%)

Bozor ochiq: Aug 12, 2026, 1:10 PM EDT

88.14

+0.09 (0.10%)

Oldingi bozordan keyin: Aug 11, 2026, 7:56 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Liquidia Q2 Earnings Call Highlights

Liquidia Q2 Earnings Call Highlights

Liquidia NASDAQ: LQDA reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical pipeline.

Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates

Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates

Liquidia Corporation (LQDA) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.7 per share. This compares to a loss of $0.49 per share a year ago.

Liquidia Corporation Reports Second Quarter 2026 Financial Results

Liquidia Corporation Reports Second Quarter 2026 Financial Results

YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated between launch in June 2025 and July 31, 2026 Recorded fourth consecutive quarter of increasing profitability, with net income of $74.7 million, adjusted EBITDA of $96.3 million and an increase in cash and cash equivalents of $61.4 million compared to the first quarter of 2026 Progressing 10 clinical studies supporting YUTREPIA and L606 across known and new indications for inhaled treprostinil MORRISVILLE, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the second quarter ended June 30, 2026.

3 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, PBF & FET

3 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, PBF & FET

Liquidia, PBF Energy and Forum Energy Technologies pair low beta with positive momentum and growth drivers amid market volatility.

3 Top Ranked Stocks Breaking Out Now

3 Top Ranked Stocks Breaking Out Now

Lenovo Group, Victoria's Secret and Liquidia Corporation are three stocks from very different industries benefitting from the same catalysts.

Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?

Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?

LQDA heads into its Q2 earnings with Yutrepia driving growth, rising profitability and a self-funded pipeline as investors watch quarterly performance.

Videolar

No Data

There is no data to display

Press-relizlar

Liquidia Corporation Reports Second Quarter 2026 Financial Results

Liquidia Corporation Reports Second Quarter 2026 Financial Results

YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated between launch in June 2025 and July 31, 2026 Recorded fourth consecutive quarter of increasing profitability, with net income of $74.7 million, adjusted EBITDA of $96.3 million and an increase in cash and cash equivalents of $61.4 million compared to the first quarter of 2026 Progressing 10 clinical studies supporting YUTREPIA and L606 across known and new indications for inhaled treprostinil MORRISVILLE, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the second quarter ended June 30, 2026.